Abstract:Since March 2018, China has conducted five rounds of negotiations for the inclusion of drugs in the medical insurance system and implemented eight batches of centralized drug procurement. The role of the medical insurance department as a strategic purchaser in the pharmaceutical market has been continuously strengthened, playing a crucial role in controlling the unreasonable growth of medical expenses and reducing the economic burden on patients. The policy of centralized drug procurement, by exchanging quantity for price, can significantly reduce drug prices and lower the profit level of companies. However, being included in the centralized drug procurement catalog can bring a substantial and stable market share to the winning companies. Therefore, the impact of the centralized drug procurement policy on the operational performance of winning companies and how their business decisions should be adjusted remain to be thoroughly explored from both theoretical and empirical perspectives. To assess the impact of the centralized drug procurement policy on the operational performance of companies, this study takes publicly listed pharmaceutical manufacturing companies from 2016 to 2020 as the sample and conducts empirical analysis using methods such as difference in difference (propensity score) matching (PSM-DID). The results showed that the centralized volume-based procurement of drugs policy had a significant negative impact on the business performance of bidding listed pharmaceutical manufacturing companies, indicating that the increase in the sales of bidding drugs could not fully make up for the profit loss caused by the price reduction in the short term. Pharmaceutical manufacturing companies should further adjust their market competition strategies, actively engage in research and development innovation. The government should guide pharmaceutical companies to improve their operational performance while ensuring the quality of drug supply by optimizing the supporting innovative incentive policies in the centralized drug procurement policy.

Exploring the Impact of Private Equity Investment on Corporate Performance: A Case Study Pharmablock

Empirical Research on M&A Performance of Private Enterprises in China

An analysis on the effect of private placement by Chinese listed companies

The Impact of Private Equity on Corporate Innovation

Efficiency Analysis of Equity Incentive in Private Listed Companies-By Taking the Example of By-Health

Private Equity Investment and Corporate Technological Innovation: An Empirical Examination Based on Chinese Mainboard-listed High-Tech

Does Private Equity Improve the Efficiency in the Firm?——The evidence from Chinese Financial Market

Research on the motivation and economic benefit of LBX Pharmacy Chain Joint Stock Company

Impact of State‐Owned Equity Participation on the Risk‐Taking Capacity of Private Enterprises in China: Insights From a Quasinatural Experiment

The Impact of Different Financing Methods on Enterprise Performance: Evidence from Chinese High-tech Companies

Changes in Financial Performance of BL Pharmaceuticals before and After the Equity Incentive Plan and Its Implications

Research on the impact of technology mergers and acquisitions on corporate performance: an empirical analysis based on China's pharmaceutical industry

Private Equity Investment, Executive Motivation and Corporate Research and Development

Listed Company Mergers and Acquisitions, Private Placement and Earnings Management

Study on the Impact Mechanism of External Mergers and Acquisitions and Internal Productivity of Enterprises on Enterprise Performance

Private Equity Funded Enterprise Financing:Capital Market Positioning and Double-Sword Effect

State equity participation and financing constraints of private enterprises in China: Based on the competitive pressure perspective

Study on the Impact of Private Enterprises' Participation in the Mixed Reform of State-owned Enterprises on the Value Preservation and Appreciation of State-owned Assets

Equity Concentration and Balance,Government Intervention and Corporate Performances Under Crisis Environment——Based on Empirical Evidence of Listed Companies in Pharmaceutical Industry

A meta-analysis on private equity technology-driven value creation

Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises